

Experimental Medicine Training Initiative /
BPS Clinical Pharmacology National Training Event

Challenges and advances in next- generation therapeutics

FRIDAY, 28TH JANUARY 2012

ON-LINE

SCHEDULE		SPEAKERS
2.00 p.m.	Clinical advantages of extended half-life antibodies – two case studies	Dr Philip Ambery Global clinical head - AstraZeneca
2.40 p.m.	Self-amplifying RNA, a step-change in nucleotide therapeutics	Dr Claire Dobson Executive Director, Discovery Sciences - AstraZeneca
3.20 p.m.	Turning human peptides and proteins into new medicines	Dr Lutz Jermutus VP and Head of Projects Early CVRM - AstraZeneca

BIOGRAPHIES



Dr Philip Ambery - Global clinical head - AstraZeneca

'Phil is an experienced pharma professional with nearly 20 years industry experience across phase 1 to phase 4, and in medical affairs to a global level. He is a physician with dual fellowship of the Royal College of Physicians and Faculty of Pharmaceutical Medicine. His experience is extensive across the cardiovascular, metabolic and renal trials arena, and he is currently a Global Clinical Head in AstraZeneca in Sweden. He is also a Consultant Physician who practises in Cambridge, UK, and takes on specialist work with the General Medical Council in the UK when required.'



Dr Claire Dobson - Executive Director and Head of In vivo Expressed Biologics, Discovery Sciences – AstraZeneca

Claire is a protein engineer with over 20 years' experience of drug discovery research in advancing protein and antibody based therapeutics. She has contributed to the discovery of five marketed and clinical assets.

Claire is currently leading AstraZeneca's In vivo Expressed Biologics (IVEB) platform. This technology involves introducing the genetic code for a therapeutic biologic into the patient's body and enabling their own tissues to produce the therapeutic biologic as required. Various approaches to introduce the genetic code into the specific organs are being developed and include adeno-associated virus (AAV), DNA vectors and mRNA.



Dr Lutz Jermutus VP and Head of Projects Early CVRM - AstraZeneca

Lutz is an inventor, contributor, and project leader for more than 20 clinical drug candidates across oncology, inflammation, cardiovascular and metabolism including oleclumab (Ph3), cotadutide (Ph2), mavrimumab (Ph2/3), Lumoxiti (moxetumumab pasudotox) and Adtralza (tralokinumab). He is a protein engineering expert with an interest in experimental medicine.